Sipuleucel T

Sipuleucel T Chemische Eigenschaften,Einsatz,Produktion Methoden

• Beschreibung

  Sipuleucel-T is the first FDA-approved therapeutic cancer vaccine. It is approved for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant (hormone-refractory) prostate cancer. Sipuleucel-T is described as a therapy rather than a precisely defined therapeutic agent because it is an autologous vaccine that is generated from each individual patient's own blood cells.

• Originator

  Dendreon (United States)

• Trademarks

  Provenge

Sipuleucel T Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(4)Suppliers